Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Randomized Trial of High-Dose Versus Conventional Dose Octreotide Acetate Versus Loperamide in the Treatment of Chemotherpay-Related Diarrhea in Patients With Colorectal Cancer
Sponsor: Cancer and Leukemia Group B
This PHASE3 trial investigates Colorectal Cancer and Diarrhea and is currently completed. Cancer and Leukemia Group B leads this study, which shows 9 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Dec 2020 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 1997
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer and Leukemia Group B
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .